Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | trastuzumab and hyaluronidase-oysk injection |
Trade Name | Herceptin Hylecta |
Synonyms | |
Drug Descriptions |
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is an injectable formulation consists of Herceptin (trastuzumab) and hyaluronidase, which demonstrates anti-tumor activity against ERBB2 (HER2)-positive breast cancer (PMID: 28625777). Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is FDA-approved for use in patients with Erbb2 (Her2)-overexpressing and/or Erbb2 (Her2) amplified breast cancer (FDA.gov). |
DrugClasses | HER2 (ERBB2) Antibody 76 |
CAS Registry Number | NA |
NCIT ID | C158060 |